Targeting PDGFR, EGFR, FGFR, and VEGFR: Key Receptor Tyrosine Kinases‐Driven Metabolic Reprogramming in Pulmonary Arterial Hypertension
Medicinal Research Reviews · 2026-01 · 46 (1) · 299-315
DOI: 10.1002/med.70014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 29.09.2025. Verfasst von Yanfei Mo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Receptors, Platelet-Derived Growth Factor, ErbB Receptors, Receptors, Fibroblast Growth Factor, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 127 Literaturangaben. Gefördert von: This study was supported by a grant from the National Natural Science Foundation of China (Grant no. 81803530)..
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a rare and life‐threatening pulmonary vascular disease distinguished by vasoconstriction and remodeling of the pulmonary artery, leading to sustained elevated pulmonary artery pressure, right ventricular failure, and even death. Receptor tyrosine kinases (RTKs) are critical in PAH pathogenesis, and targeted therapies against RTKs are becoming a research hotspot due to their potential to inhibit cell proliferation and right ventricular hypertrophy. Abnormal activation of RTKs induces downstream signaling cascades, including metabolic reprogramming through multiple regulatory crosstalk, to meet high energy requirements during cell proliferation. However, the crucial connection between metabolic reprogramming and RTKs in PAH remains largely unexplored. In this review, we focus on four key RTKs: Platelet‐Derived Growth Factor Receptor (PDGFR), Epidermal Growth Factor Receptor (EGFR), Fibroblast Growth Factor Receptor (FGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR) in the metabolic reprogramming of PAH and explore hypotheses that require further validation. The aim is to highlight how these mechanisms can be applied to develop better therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
ORCID-Profile: Yang Bai
Förderung
- This study was supported by a grant from the National Natural Science Foundation of China (Grant no. 81803530).
Zitieren
APA
Mo, Y., Wang, D., & Bai, Y. (2026). Targeting PDGFR, EGFR, FGFR, and VEGFR: Key Receptor Tyrosine Kinases‐Driven Metabolic Reprogramming in Pulmonary Arterial Hypertension. Medicinal Research Reviews, 46(1), 299-315. https://doi.org/10.1002/med.70014
Vancouver
Mo Y, Wang D, Bai Y. Targeting PDGFR, EGFR, FGFR, and VEGFR: Key Receptor Tyrosine Kinases‐Driven Metabolic Reprogramming in Pulmonary Arterial Hypertension. Medicinal Research Reviews. 2026;46(1):299-315. doi:10.1002/med.70014
BibTeX
@article{Mo2026,
author = {Mo, Yanfei and Wang, Desheng and Bai, Yang},
title = {Targeting PDGFR, EGFR, FGFR, and VEGFR: Key Receptor Tyrosine Kinases‐Driven Metabolic Reprogramming in Pulmonary Arterial Hypertension},
journal = {Medicinal Research Reviews},
year = {2026},
volume = {46},
number = {1},
pages = {299--315},
doi = {10.1002/med.70014}
}
EUVIMED